Denne kliniske effekt var efter 2 ugers behandling forbundet med en højere reduktion i bcr- abl transkriptionen hos de imatinibbehandlede patienter end i kemoterapiarmen (p=0, 02).
This clinical effect was associated with a higher reduction in bcr- abl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02).